#1 Clinical Trials Search in Europe

LTG-001

Clinical trials are investigating LTG-001 in people with osteoarthritis of the knee. This article explains what the studies aim to measure, including pain relief and safety, and who may take part. The trial data describe a phase 2 study comparing LTG-001 with placebo.

Table of contents

Trial overview

The available clinical trial is studying LTG-001 in people with osteoarthritis of the knee, a joint condition that can cause pain and stiffness.[1] The study is designed to see whether LTG-001 can improve pain compared with placebo.[1]

This is an interventional study, which means researchers give a study treatment and then compare the results between groups.[1] The trial is listed as Phase 2 and is currently authorised.[1]

Who can participate

The target population is people with osteoarthritis of the knee.[1] The trial data do not give more detailed inclusion or exclusion rules, so the main known requirement is the condition being studied.[1]

In simple terms, this means the study is meant for adults or patients who already have knee osteoarthritis, but the exact age limits and other entry rules are not provided in the source data.[1]

Study design and treatment comparison

The study compares LTG-001 with a matched placebo, meaning a look-alike treatment used to make the comparison fair.[1] The intervention list shows LTG-001 as a tablet taken by oral use, but the trial data should be read as study information rather than general treatment advice.[1]

The brief summary says the study aims to evaluate the efficacy of LTG-001 versus placebo for pain associated with knee osteoarthritis.[1] Efficacy means how well a treatment works under study conditions.[1]

What is being measured

The main endpoint, or main result being measured, is the change in WOMAC pain subscale score from before treatment to the end of each treatment period.[1] WOMAC is a patient-reported questionnaire used to measure pain and function in arthritis studies.[1]

The trial measures this score at multiple time points, including Day 1 and Day 28 at the start of each treatment period, and Day 14 and Day 41 at the end of each treatment period.[1] This helps researchers see whether pain changes during the study periods.[1]

Trial status and size

The study is authorised, which means it has approval to proceed.[1] The planned enrollment is 180 people, so the trial is designed to include a moderate number of participants.[1]

Because the trial is Phase 2, the study is still in an early-to-mid stage of testing rather than a final confirmation stage.[1] The main focus is on whether LTG-001 can help with knee pain and how the results compare with placebo.[1]

Trial ID Phase Condition studied Status Enrollment
2025-522755-26-01 Phase 2 Osteoarthritis of the knee Authorised 180

FAQ

  • What is being studied in LTG-001 trials? The trial is studying whether LTG-001 can help reduce pain in osteoarthritis of the knee. It also compares LTG-001 with a matched placebo.
  • Who can take part in the study? The study is focused on people with osteoarthritis of the knee. The trial data do not list more detailed entry rules.
  • What phase is the LTG-001 study? The study is a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment works and continue safety checks.
  • What outcome is the study measuring? The main outcome is the change in WOMAC pain score. This measures pain in daily life before and after each treatment period.
  • How many people are planned for the study? The trial plans to enroll 180 people. This helps researchers compare results between LTG-001 and placebo.

Ongoing Clinical Trials on LTG-001

  • A Study Testing How Well LTG-001 Works and Its Safety in Patients with Knee Osteoarthritis

    Not yet recruiting

    1
    Investigated drugs:
    Denmark

Glossary

  • Osteoarthritis: A common joint condition where the joint becomes painful and stiff over time.
  • Knee osteoarthritis: Osteoarthritis that affects the knee joint and can cause pain with walking, bending, or daily activity.
  • Phase 2: A mid-stage clinical trial that looks at early signs of benefit and continues to monitor safety.
  • Interventional study: A study where researchers give a treatment and compare the results with another group.
  • Placebo: A treatment that looks like the study drug but does not contain the active study medicine.
  • Matched placebo: A placebo designed to look the same as the study treatment so the comparison is fair.
  • Enrollment: The number of people planned to join a study.
  • Outcome: A result that researchers measure to see whether the treatment is helping.
  • Primary outcome: The main result the study is designed to measure.
  • WOMAC pain subscale: A questionnaire score used to measure pain from arthritis, especially in the knee and hip.
  • Treatment period: A set time during which a participant receives a study treatment.